Rights and permissions
About this article
Cite this article
Targeting DES use to high-risk patients is cost saving. Pharmacoecon. Outcomes News 659, 8 (2012). https://doi.org/10.2165/00151234-201206590-00023
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206590-00023